Sign Out
Caution in patients with severe renal impairment (Creatinine clearance less than 25 mL/minute) and with moderate to severe hepatic impairment. May cause cardiovascular risks and lesions including endocardial hemorrhage, hemosiderin deposition and fibrosis in the left ventricle, hemorrhage and necrosis of the smooth muscle in the wall of the coronary artery, intimal thickening of the coronary artery and coronary arteritis and periarteritis.
There are no adequate and well-controlled studies on its use in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus. Cilostazol is distributed into milk in rats, discontinue nursing or drug therapy.
Safety and efficacy in children have not been established.
Continue with Google